What's Hot

    ‘Sunrise on the Reaping’ Opens in Theaters With $100 Million Weekend in Sight

    November 20, 2026

    Trump, Xi and Putin Meet in Shenzhen for First Three-Way Talks at APEC

    November 20, 2026

    Anthropic Prices IPO at $83 a Share, Valuing the AI Company at About $1.5 Trillion

    November 20, 2026
    Facebook Twitter Instagram
    Breaking
    • ‘Sunrise on the Reaping’ Opens in Theaters With $100 Million Weekend in Sight
    • Trump, Xi and Putin Meet in Shenzhen for First Three-Way Talks at APEC
    • Anthropic Prices IPO at $83 a Share, Valuing the AI Company at About $1.5 Trillion
    • Muslims Projected to Become the World’s Largest Religious Group by 2035, Pew Finds
    • Nvidia Doubles Revenue to $115.8 Billion in First Report Since Jensen Huang’s Exit
    • What Grounded Every U.S. Flight: FAA Traces Outage to Router Work in Arkansas
    • McCaffrey Sets NFL Record as 49ers Outlast Cowboys 46-40 in Dallas Shootout
    • FDA Approves Sunharbo, the First Drug in a New Class to Prevent a Second Stroke
    Friday, November 20
    MiniGoogle
    • U.S.
    • World
    • Politics
    • Business
    • Tech
    • Science
    • Health
    • Sports
    • Entertainment
    Facebook Twitter Instagram
    MiniGoogle
    Home»Health»FDA Approves Sunharbo, the First Drug in a New Class to Prevent a Second Stroke
    Health

    FDA Approves Sunharbo, the First Drug in a New Class to Prevent a Second Stroke

    adminBy adminNovember 20, 2026No Comments2 Mins Read
    MiniGoogle Health news graphic: FDA approves a new kind of stroke drug
    Share
    Facebook Twitter LinkedIn Pinterest Email
    The story in 100 words

    The FDA has approved Sunharbo (asundexian), Bayer's once-daily pill to lower the risk of another stroke in adults who recently had a mild-to-moderate ischemic stroke or a high-risk mini-stroke. It is the first approved factor XIa inhibitor, a new type of blood thinner designed to stop harmful clots while limiting bleeding. The approval rests on the OCEANIC-STROKE trial of 12,327 patients, which found fewer repeat strokes without a significant rise in major bleeding. Sunharbo is taken alongside standard antiplatelet medicines. Doctors welcomed the option but say cost and insurance access could slow early use.

    People who survive a stroke face a high risk of having another one soon after. A newly approved pill offers a different way to lower that risk.

    How it works

    Sunharbo blocks factor XIa, a clotting protein thought to drive dangerous clot growth more than the body's normal ability to stop bleeding. That is why researchers hope this drug class can prevent strokes with fewer bleeding problems than older blood thinners.

    The evidence

    In the OCEANIC-STROKE trial, patients taking Sunharbo with standard antiplatelet therapy had fewer recurrent ischemic strokes than those on placebo. Gastrointestinal bleeding was somewhat more common, but major bleeding did not rise significantly.

    • Approved: November 2026
    • Dose: one 50 mg tablet daily
    • Who it's for: adults after a recent non-cardioembolic ischemic stroke or high-risk TIA
    • Trial size: 12,327 patients

    What to know

    This is general news, not medical advice. Anyone who has had a stroke or mini-stroke should talk with their doctor about whether a new treatment is right for them.

    Related on MiniGoogle

    • NASA Launches $1 Million Challenge for Students to Help Design a Moon Base
    • Muslims Projected to Become the World's Largest Religious Group by 2035, Pew Finds
    • More Health news

    Sources

    • FDA press release via HMP Global
    • WebMD: FDA approves Sunharbo
    • TCTMD: Asundexian approval

    MiniGoogle summarizes reporting from the outlets above in our own words. Figures are as reported at the time of publication.

    FDA Medicine Stroke
    admin
    • Website

    Add A Comment

    Leave A Reply Cancel Reply

    Editors Picks
    Latest Posts

    Get the Daily Brief

    The top U.S. and world stories, 100 words each, every morning.

    Stay informed, in 100 words.

    Read today's stories →
    MiniGoogle

    The biggest U.S. and world stories, distilled into 100 words each. Fast, clear and free, for people who want the facts without the noise.

    Sections

    • U.S.
    • World
    • Politics
    • Business
    • Tech
    • Health

    Company

    • About Us
    • Contact
    • Editorial Policy
    • Privacy Policy
    • Terms of Use

    The Daily Brief

    Top stories, 100 words each, in your inbox every morning.

    MiniGoogle
    © MiniGoogle. All rights reserved.
    PrivacyTermsContact

    Type above and press Enter to search. Press Esc to cancel.